In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
The therapeutic efficacy of four quinolones, i.e. ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid, was investigated in experimental infections in mice caused by pipemidic acid-susceptible and -resistant E. coli. For intraperitoneal infections caused by E. coli strain 444 and 23, the efficacy of ciprofloxacin, ofloxacin and norfloxacin was superior to that of pipemidic acid. Furthermore, ciprofloxacin and ofloxacin had higher activity than norfloxacin and pipemidic acid in urinary tract and uterine infections. Serum and uterus levels of ciprofloxacin and ofloxacin in normal mice were higher and more durable than those of norfloxacin.
Obana
Y
Y
Department of Microbiology, Kyoto Pharmaceutical University, Japan.
Nishino
T
T
D000818:Animals; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D051379:Mice; D008826:Microbial Sensitivity Tests; D009503:Neutropenia / Q000150:complications; D009643:Norfloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use; D010876:Pipemidic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use; D013997:Time Factors; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology; D014599:Uterus / Q000378:metabolism
D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D015242:Ofloxacin; D010876:Pipemidic Acid; D009643:Norfloxacin